title: Hypoactive sexual desire among depressed female patients treated with selective serotonin reuptake inhibitors: a comparison between escitalopram and fluoxetine.
abstract: OBJECTIVE
  To determine the risk of hypoactive sexual desire (HSD) in depressed female patients treated with selective serotonin reuptake inhibitors, comparing escitalopram and fluoxetine. The associated factors were also examined.
  
  
  METHODS
  This cross-sectional study involved 112 female patients (56 in each group) diagnosed to have major depressive disorder who were in remission (as defined by the Diagnostic and Statistical Manual-IV (DSM-IV) in the past 2 months and the Montgomery-Asberg Depression Rating Scale (MADRS) score of ≤ 10) from the psychiatric clinic, University Kebangsaan Malaysia Medical Centre (UKMMC). They were interviewed using the Structured Clinical Interview for DSM-IV (SCID). Hypoactive sexual desire was assessed using the Desire subscale of the Malay Version of the Female Sexual Function Index (MVFSFI).
  
  
  RESULTS
  The risk of hypoactive sexual desire was 50.9% for all patients; 64.3% for the fluoxetine group and 37.5% for the escitalopram group. Multivariate logistic regression analysis showed fluoxetine therapy (adjusted OR = 3.08, CI = 1.23, 7.73) and moderate to high dosage of antidepressant (adjusted OR = 4.27, CI = 1.66, 10.95) were significantly associated with hypoactive sexual desire.
  
  
  CONCLUSIONS
  Those treated with fluoxetine had significantly higher rates of HSD than those on escitalopram. Moderate to high antidepressant dosage is another significant predictor of HSD in depressed women treated with SSRIs.
authors: Department of Psychiatry, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
authors: Hatta
authors: H
authors: Sidi
authors: Duni
authors: D
authors: Asmidar
authors: Rozita
authors: R
authors: Hod
authors: Nik Ruzyanei Nik
authors: NR
authors: Jaafar
authors: Ng Chong
authors: NC
authors: Guan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015283:Citalopram / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000453:epidemiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007406:Interview, Psychological; D008296:Malaysia / Q000453:epidemiology; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D011569:Psychiatric Status Rating Scales; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012725:Sexual Behavior / Q000187:drug effects / Q000208:ethnology / Q000523:psychology; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology*; D019529:Sexuality / Q000187:drug effects / Q000208:ethnology / Q000523:psychology; D055815:Young Adult
chemical_list: D015283:Citalopram; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors